Related Experiment Video

Updated: Aug 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Re-induction of hormonal sensitivity in hormone-refractory prostate cancer--fact or fiction?

William R Berry1

  • 1US Oncology, Houston, TX, USA. william.berry@usoncology.com

Nature Clinical Practice. Oncology
|November 3, 2005
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Aug 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.

Prostate cancer and prostatic diseases·2024

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.

European urology oncology·2023

Examining health care champions: a mixed-methods study exploring self and peer perspectives of champions.

Implementation research and practice·2023

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.

European urology·2022

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021

Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.

International journal of radiation oncology, biology, physics·2020

Effect of bisphosphonates on pain and quality of life in patients with bone metastases.

Nature clinical practice. Oncology·2009

Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors.

Nature clinical practice. Oncology·2009

Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck.

Nature clinical practice. Oncology·2009

Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.

Nature clinical practice. Oncology·2009

Xoft Axxent electronic brachytherapy: a new device for delivering brachytherapy to the breast.

Nature clinical practice. Oncology·2009

Unintended pregnancy during radiotherapy for cancer.

Nature clinical practice. Oncology·2009

Radiotherapy Advances for Cervical Spine Tumors: Conventional Versus Stereotactic Body Radiotherapy (SBRT).

Clinical spine surgery·2026

Reirradiation With Proton Therapy Using Hypofractionated Schedules: A Systematic Review of the Literature.

International journal of particle therapy·2026

Environmental and Occupational Risk Factors for Retinoblastoma.

AJPM focus·2026

Chest wall pain as a late effect following radiotherapy for breast cancer: A systematic review of prevalence and risk factors.

Technical innovations & patient support in radiation oncology·2026

Comparative Cost Modeling of Out-of-Pocket Costs for External Beam Radiation Therapy Versus Stereotactic Body Radiation Therapy in Metastatic Spine Cancer.

Cureus·2026

Adjuvant volumetric modulated arc therapy for incompletely resected type II pleuropulmonary blastoma: a case report.

Oxford medical case reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us